Asthma Clinical Trial
Official title:
Smartphone App for Asthma Self-care: Assessment of Outcomes (Asthma Progession and Costs)
Verified date | July 2023 |
Source | Ministry of Science and Technology, Taiwan |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goal of this clinical trial is to investigate whether a smartphone app based on the Global Initiative for Asthma (GINA) guidelines can improve asthma control and quality of life, and decrease asthma-related costs in children. The main question it to answer whether this app can improve asthma control, increase the quality of life, and decrease asthma-related costs. Participants in the intervention group downloaded the asthma smartphone app, and followed up monthly via phone calls and clinic visits, while the control group received reminder calls. Researchers will compare with the control group to see if the intervention receives more asthma control improvement.
Status | Completed |
Enrollment | 140 |
Est. completion date | June 1, 2021 |
Est. primary completion date | June 1, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 3 Years to 18 Years |
Eligibility | Inclusion Criteria: - aged between 3 and 18 years; - who had access to the smartphone app; - with asthma treatment steps 2-4, requiring regular treatment with controller medication (for at least 6 months over the past year) according to the GINA guidelines; - who had at least two clinic or emergency department visits related to asthma in the previous year. Exclusion Criteria: - Children who had comorbidities, or other major medical problems, and who did not have a smartphone or whose caregivers did not have a smartphone were excluded from the study. |
Country | Name | City | State |
---|---|---|---|
Taiwan | Taipei Hospital, Ministry of Health and Welfare | Taipei City | Taipei |
Lead Sponsor | Collaborator |
---|---|
Ministry of Science and Technology, Taiwan | Taipei Hospital, Ministry of Health and Welfare |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of participants both in intervention and control were assessed for the asthma severity change using Global Strategy for Asthma Management and Prevention (GINA) Guideline | The physician diagnoses asthma change at Taipei Hospital | 3 and 6 months evaluation | |
Primary | All participants were assessed for the Asthma Control Test (ACT) change using ACT questionnaire from quality metric incorporated | The physician evaluate ACT change at Taipei Hospital for both group | 3 and 6 months evaluation | |
Primary | All participants were assessed for the change of Quality of life using MiniPAQLQ | Physician and researchers evaluate the quality of life using MiniPAQLQ questionnaire | 3 and 6 months evaluation | |
Primary | All participants were assessed for the Asthma Control Test change using Paediatric Asthma Quality of Life Questionnaire (PAQLQ) questionnaire | The physician evaluate PASS score change at Taipei Hospital for both group | 3 and 6 months evaluation | |
Primary | All participants were assessed for the Peak Expiratory Flow (PEF) change using spirometry | The physician evaluate PEF change at Taipei Hospital for both group | 3 and 6 months | |
Primary | All participants were assessed for the change of asthma cost using direct and indirect costs from national website | Researchers access the data from National Health Insurance database | 3 and 6 months | |
Secondary | All participants were assessed for their age in the baseline using data of birthday information | Nurses and or researchers is responsible in filling the data from the patient admission in the Hospital | Baseline | |
Secondary | All participants were assessed for the total serum IgE (kU/I) change from blood assessment | The researcher and physician record and evaluate the data | 3 and 6 months evaluation | |
Secondary | All participants were assessed for the comorbidities with atopic dermatitis using the health data record from Hospital and National Health Insurance | The researcher and physician record and evaluate the data | Baseline | |
Secondary | All participants were assessed for the comorbidities with allergic rhinitis using the health data record from Hospital and National Health Insurance | The researcher and physician record and evaluate the data | Baseline | |
Secondary | All participants were assessed for the family history of atopic disease using the health data record from Hospital and National Health Insurance | The researcher and physician record and evaluate the data | Baseline | |
Secondary | All participants were assessed for the systemic steroid dosage (prednisolone, mg), using the health data record from Hospital and National Health Insurance | The researcher and physician record and evaluate the data | Baseline | |
Secondary | All participants were assessed for the ICS Dosage (Seretide,mcg), using the health data record from Hospital and National Health Insurance | The researcher and physician record and evaluate the data | Baseline | |
Secondary | All participants were assessed for the Anti-leukotriene (montelukast, tab), using the health data record from Hospital and National Health Insurance | The researcher and physician record and evaluate the data | Baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|